Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Astrazeneca PLC (NYSE:AZN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
Astrazeneca PLC pays an annual dividend of $1.37 per share and has a dividend yield of 4.0%. Adamis Pharmaceuticals Corporation does not pay a dividend. Astrazeneca PLC pays out 44.9% of its earnings in the form of a dividend.
Risk & Volatility
Adamis Pharmaceuticals Corporation has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, Astrazeneca PLC has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.
This is a summary of current recommendations for Adamis Pharmaceuticals Corporation and Astrazeneca PLC, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamis Pharmaceuticals Corporation||0||0||3||0||3.00|
Adamis Pharmaceuticals Corporation presently has a consensus price target of $9.83, suggesting a potential upside of 91.87%. Astrazeneca PLC has a consensus price target of $36.40, suggesting a potential upside of 5.10%. Given Adamis Pharmaceuticals Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than Astrazeneca PLC.
This table compares Adamis Pharmaceuticals Corporation and Astrazeneca PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamis Pharmaceuticals Corporation||-158.51%||-69.03%||-47.51%|
Institutional and Insider Ownership
10.1% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. Comparatively, 14.2% of Astrazeneca PLC shares are owned by institutional investors. 12.2% of Adamis Pharmaceuticals Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Adamis Pharmaceuticals Corporation and Astrazeneca PLC’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Adamis Pharmaceuticals Corporation||$11.39 million||14.11||-$18.97 million||N/A||N/A|
|Astrazeneca PLC||$21.74 billion||4.03||$5.91 billion||$3.05||11.35|
Astrazeneca PLC has higher revenue and earnings than Adamis Pharmaceuticals Corporation.
Astrazeneca PLC beats Adamis Pharmaceuticals Corporation on 9 of the 14 factors compared between the two stocks.
Adamis Pharmaceuticals Corporation Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.